| Name | Title | Contact Details |
|---|
Founded in 2012 by international bestselling authors, work-life balance experts, and holistic healthcare providers, Dr. Dave Braun and Dr. Troy Amdahl, Oola provides a simple and easy-to-follow lifestyle framework designed to lead you, step by step, to a life of less stress, more personal growth, and a clearer path toward living your unique purpose. The concept originally ideated in 1997 as Dr. Braun and Dr. Amdahl worked to better themselves in the seven key areas of life -- Fitness, Finance, Family, Field (career), Faith, Friends, and Fun. Since then, the Oola lifestyle has become a global phenomenon, with over a million followers in 40 countries actively creating their best lives. In 2021, Oola announced an affordable personal development eLearning platform to add to their offerings. Expected to launch in Summer 2021, the new platform will accelerate Oola`s goal of impacting one billion lives in seven years.
Assembly Biosciences (NASDAQ: ASMB) is a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome. The HBV program is focused on advancing a new class of potent, oral core inhibitors that have the potential to increase cure rates for chronically infected patients. The microbiome program is developing novel oral live microbial biotherapeutic candidates with Assembly`s fully integrated platform, including a robust process for strain identification and selection, GMP banking and production, and targeted delivery to the lower gastrointestinal tract with the GEMICEL® technology. We pride ourselves on creating a culture and work environment that is scientifically driven, ambitious, and collaborative. We encourage diversity of thought that leads to great innovation and are looking to add to our dynamic team great people who are driven to transform the lives of patients. We believe our Microbiome platform represents a best in class approach to developing biopharmaceutical agents from live biotherapeutic products. ABI-M201, our lead program in mildly to moderately active ulcerative colitis (UC), is currently in a phase 1b clinical trial. This program is part of a broader collaboration we established with Allergan in 2017 for gastrointestinal programs such as UC, Crohn`s disease and Irritable Bowel Syndromes with potential total development and commercial milestones of up to $2.8 billion. Our internal pipeline comprises first in class or best in class live microbial biotherapeutic approaches in areas such as oncology, immune mediated and metabolic disorders, and other areas of high medical need. Assembly is headquartered in Carmel, Indiana, while the R&D headquarters is in South San Francisco. The Company also has a microbiome manufacturing facility in Groton, CT, and offices in China.
DRE Medical Inc is a Louisville, KY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Olmsted Medical Center is a Rochester, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Environmental Infection Control Consultants (EICC) is a Chalfont, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.